| Identification | Back Directory | [Name]
2-(4-chlorophenyl)-N-[4-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide | [CAS]
370854-75-4 | [Synonyms]
WAY-321366
Benzeneacetamide, 4-chloro-N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]-
2-(4-chlorophenyl)-N-[4-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide | [Molecular Formula]
C20H14ClN3O3 | [MOL File]
370854-75-4.mol | [Molecular Weight]
379.8 |
| Hazard Information | Back Directory | [Uses]
Tyrosine kinase-IN-9 (Compound B) is the inhibitor for c-Abl. Tyrosine kinase-IN-9 can be used in research of neurodegenerative diseases including Alzheimer’s and Parkinson’s disease[1]. | [Definition]
ChEBI: 2-(4-chlorophenyl)-N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide is a member of acetamides. | [References]
[1] Palakurti R, et al., Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics. J Biomol Struct Dyn. 2017 Mar;35(4):883-896. DOI:10.1080/07391102.2016.1166454 |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|